跳至主要内容
临床试验/NCT07121803
NCT07121803招募中不适用

Analysis of Effects of Specialized Food Products Based on Ice-Cream on Esophageal Motility

Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2025年7月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
30
试验地点
1
主要终点
Mean contractile front velocity

研究概览

简要总结

This study aims to assess the influence of specialized products based on ice cream on esophageal motility

详细描述

During this study participants will be examined with the use of high-resolution esophageal motility. After standard procedure, according to Chicago IV protocol, subjects will be provided with 3 different types of food products: standard icecream (sundae), icecream with brazzein, maltitol and oligofructose; icecream with brazzein, erythritol, maltitol and inulin. Tolerability of products will be assessed based on specialized scales and formal questioning.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •willingness to participate based on signed written informed consent;
  • •controlled glycemia. If stable glycemia is achieved on treatment, the following requirements should be met:
  • •no qualitative changes in treatment within 6 months before enrollment (i.e., the introduction of a new antidiabetic therapy);
  • •doses of anti-diabetic medications should be stable for 6 month in patients who receive metformin, gliptins, sulfonylureas, sodium/glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 agonists (GLP-1) or insulin.
  • •no new medications during participation in the study

排除标准

  • •Pregnancy and breastfeeding;
  • •Liver cirrhosis based on liver histology, or liver stiffness measurement (LSM > or = 14 kPa by Fibroscan), or APRI > or= 1; or BARD score > or =
  • •Diarrhea of any type (watery stool more than 3 times a day).
  • •Chronic heart failure (I-IV class by NYHA).
  • •Past major abdominal or chest surgery, including bariatric procedures and fundoplication (except appendectomy or cholecystectomy performed more than a year before enrollment).
  • •Achalasia and esophago-gastric junction outflow obstruction
  • •Major esophageal motility disorders according to Chicago IV classification.
  • •Clinically relevant acute cardiovascular event within 6 months prior to screening.
  • •Uncontrolled arterial hypertension despite optimal anti-hypertensive therapy.
  • •Diabetes mellitus type
  • •The level of glycated hemoglobin [HbA1c] >9.0%.
  • •Hypersensitivity to the studied product or any of its components, including lactose intolerance.
  • •The intake of any pharmaceutical agents with known influence on esophageal motility (including, but not limited to: beta-blockers, calcium channel blockers, m-cholinoblockers, myorelaxants, antidepressants, tranquilizers, prokinetic agents)
  • •Any medical conditions that may significantly affect life expectancy, including known cancers;
  • •Any clinically significant immunological, endocrine, hematological, gastrointestinal, neurological, tumor or psychiatric diseases;
  • •Mental instability or incapacity, which may impact the ability to give informed consent, take part in the study, or affect the ability to comply with the requirements of the study protocol;
  • •Inability to tolerate high-resolution esophageal manometry without sedation, at least in part.

研究组 & 干预措施

Arm 1

Experimental

Subjects of this arm will receive the following sequence of products: 1 - ice cream with brazzein, maltitol and oligofructose, 2 - ice cream with brazzein, erythritol, maltitol and inulin; 3 - standard ice cream

干预措施: specialized food based on ice cream, order 1 (Other)

Arm 2

Experimental

Subjects of this arm will receive the following sequence of products: 1 - ice cream with brazzein, erythritol, maltitol and inulin; 2 - ice cream with brazzein, maltitol and oligofructose, 3 - standard ice cream

干预措施: specialized food based on ice cream, order 2 (Other)

Arm 3

Experimental

Subjects of this arm will receive the following sequence of products: 1 - standard ice cream; 2 - ice cream with brazzein, maltitol and oligofructose, 3 - ice cream with brazzein, erythritol, maltitol and inulin

干预措施: specialized food based on ice cream, order 3 (Other)

结局指标

主要结局

Mean contractile front velocity

时间窗: baseline, during the intervention

CFV

Mean intrabolus pressure

时间窗: baseline, during the intervention

IBP

Mean lower esophageal sphincter resting pressure

时间窗: baseline, during the intervention

Based on the high-resolution esophageal manometry measurement

Distal contractile integral

时间窗: baseline, during the intervention

mean lower esophageal sphincter integral relaxation pressure

时间窗: baseline, during the intervention

IRP 4

Distal latency

时间窗: baseline, during the intervention

DL

次要结局

  • mean upper esophageal sphincter resting pressure(baseline, during the intervention)
  • product organoleptic assessment(during the intervention)
  • Mean upper esophageal sphincter integrated relaxation pressure(baseline, during the intervention)

研究者

发起方
Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology
申办方类型
Other
责任方
Principal Investigator
主要研究者

Sergey Morozov

Principal Investigator

Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology

研究点 (1)

Loading locations...

相似试验